{"meta":{"query_hash":"4e13faf04e63","filters":{"venue":"Tumors of female reproductive system"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4e13faf04e63","api":"https://metacan.xera.ac/api/v1/cohort?venue=Tumors+of+female+reproductive+system"},"results":[{"id":"W3136098766","doi":"10.17650/1994-4098-2020-16-3-72-80","title":"Lenvatinib and pembrolizumab in patients with advanced uterine cancer","year":2020,"lang":"en","type":"article","venue":"Tumors of female reproductive system","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lenvatinib; Medicine; Endometrial cancer; Internal medicine; Adverse effect; Oncology; Population; Cancer; Gynecology; Immunotherapy; Thyroid cancer","score_opus":0.019311371024029807,"score_gpt":0.27546925908504216,"score_spread":0.25615788806101236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136098766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9487142,0.038331706,0.00037355875,0.0022190895,0.00008658635,0.00008987281,0.00010264112,0.000019178891,0.010063067],"genre_scores_gemma":[0.99065757,0.0071293293,0.00037290232,0.00078975764,0.000115127346,0.000025640215,0.00010376349,0.0000019594147,0.0008040285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998889,0.000041035037,0.000013595457,0.000013698898,0.000023523888,0.000019334579],"domain_scores_gemma":[0.99992645,0.000021772343,0.000018475197,0.0000031526654,0.0000058414494,0.00002429274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021629418,0.000105170104,0.00028137147,0.00020437768,0.00023974721,0.00017292917,0.00008349851,0.0003043349,0.00060744537],"category_scores_gemma":[0.00048250557,0.00005549644,0.00017749921,0.00027436964,0.00012009455,0.00015947293,0.0001380998,0.00037476706,0.00010505455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008713612,0.0009731353,0.49521282,0.0007009307,0.00034523895,0.032206334,0.0008920994,0.000983907,0.030043256,0.00083597447,0.007843795,0.4212489],"study_design_scores_gemma":[0.0016276872,0.013132146,0.76955724,0.0003583508,0.0005852592,0.1042526,0.0006946646,0.0021383527,0.009500062,0.00094344816,0.09717321,0.00003700716],"about_ca_topic_score_codex":0.0006268307,"about_ca_topic_score_gemma":0.0017075936,"teacher_disagreement_score":0.0006268307,"about_ca_system_score_codex":0.00020265297,"about_ca_system_score_gemma":0.00027071676,"threshold_uncertainty_score":0.0020320415},"labels":[],"label_agreement":null},{"id":"W4410308781","doi":"10.17650/1994-4098-2025-21-1-123-131","title":"Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab","year":2025,"lang":"en","type":"article","venue":"Tumors of female reproductive system","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Oncology; Endometrial cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.02899208550226592,"score_gpt":0.32050949444354426,"score_spread":0.29151740894127837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410308781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985696,0.004816821,0.00017615015,0.00086894695,0.00007944367,0.000037570397,0.0050577796,0.000010230879,0.003257009],"genre_scores_gemma":[0.99544215,0.0007718074,0.0000782982,0.0001557832,0.00004882187,0.000025436073,0.0032636344,0.0000026432047,0.000211435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995752,0.00016470841,0.000049949755,0.00006541408,0.000054759654,0.000089960246],"domain_scores_gemma":[0.9988335,0.00022053134,0.0006057684,0.0000426014,0.00008483214,0.00021288477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052500126,0.00015151913,0.00036752666,0.0002969251,0.00023923615,0.0007603872,0.00022768437,0.0003688786,0.0018113124],"category_scores_gemma":[0.0031820254,0.000091496964,0.00072225457,0.00057347614,0.00018630923,0.0005891549,0.00045042226,0.00074111414,0.00021936362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008782216,0.0003406303,0.94606876,0.00035929968,0.0017369677,0.00044905738,0.00019325287,0.0016173706,0.00034644155,0.0003108193,0.005382243,0.034413036],"study_design_scores_gemma":[0.00046780426,0.002101179,0.9864559,0.00016215399,0.00090806826,0.0009921093,0.00055706804,0.0018909918,0.00019234604,0.00047125304,0.0057590483,0.00004198494],"about_ca_topic_score_codex":0.0038731827,"about_ca_topic_score_gemma":0.005972611,"teacher_disagreement_score":0.0038731827,"about_ca_system_score_codex":0.00075468683,"about_ca_system_score_gemma":0.00040450925,"threshold_uncertainty_score":0.0077012777},"labels":[],"label_agreement":null}]}